NCT00794664View on ClinicalTrials.gov

Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis

PHASE3CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

October 31, 2010

Conditions
HypercholesterolemiaCoronary Heart Disease
Interventions
DRUG

Mipomersen

200 mg (1 mL), weekly subcutaneous injections for 26 weeks

DRUG

Placebo

1 mL weekly subcutaneous injections for 26 weeks

Trial Locations (27)

7500

Cape Town

7925

Cape Town

13353

Berlin

29801

Aiken

30338

Atlanta

32792

Winter Park

33458

Jupiter

45212

Cincinnati

50937

Koln (Lindenthal)

63104

St Louis

66160

Kansas City

69120

Heidelberg

79106

Freiburg im Breisgau

02114

Boston

03301

Concord

R3A 1M5

Winnipeg

G7H 5H6

Chicoutimi

H1T 1C8

Montreal

500 05

Hardec Kralove

305 99

Pilsen

128 08

Prague

686 68

Uherské Hradiště

0157

Gauteng

0002

Pretoria

GU2 7XX

Guildford

SE1 7EH

London

MI3 9WL

Manchester

Sponsors
All Listed Sponsors
collaborator

Ionis Pharmaceuticals, Inc.

INDUSTRY

lead

Kastle Therapeutics, LLC

INDUSTRY